CAN-2409, an adenoviral vector, plus prodrug kills tumor cells and stimulates a cancer vaccine effect in men with localized intermediate- to high-risk prostate cancer reducing the risk for disease recurrence or death compared with placebo, a phase 3 trial finds. When CAN-2409 (aglatimagene besadenovec) is locally delivered and combined with the prodrug valacyclovir, immunogenic prostate tumor cell death is induced. At a median follow-up of 50.3 months, DFS was significantly prolonged 30% with CAN-2409 (hazard ratio [HR], 0.70; 95% CI, 0.52-0.94; P =.0155), Dr DeWeese reported. Patients who received CAN-2409 had a significant 38% prolonged prostate cancer-specific DFS (HR, 0.62; 95% CI, 0.44-0.87; P =.0046). The treatment-related serious adverse events (1.7% vs 2.2%) and discontinuation rates (5.4% vs 6.0%) were lower with CAN-2409.